TABLE 2.
Capsaicin, antagonist, and agonist concentrations used in the in vivo and in vitro experiments of the included studies1
| Caps concentration | Antagonist concentration, μM | ||||
|---|---|---|---|---|---|
| Reference | In vivo | In vitro, μM | Antagonist | Other agonists | |
| Baboota et al. (78) | 2 mg/kg body weight | 0.1, 0.5, 1, 10, 50, and 100 | Capsazepine | 1, 10 and 20 | Resiniferatoxin |
| Baskaran et al. (73) | 0.01% in the diet | 1 | Capsazepine | 10 | — |
| Baskaran et al. (79) | 0.003%, 0.01% and 0.03% in the diet | 1 | Capsazepine | 10 | — |
| Chen et al. (72) | 0.01% in the diet | 1 | Capsazepine | 1 | — |
| GSK0660 | 10 | ||||
| Fan et al. (77) | — | 25, 50, and 100 | T0070907 | 10 | Capsiate |
| SR59230A | 10 | ||||
| Kida et al. (75) | — | 0.1, 1, and 10 | 5'-Iodoresiniferatoxin | 200 | — |
| Kida et al. (76) | — | 0.1, 1, 10, 30, and 100 | 5'-Iodoresiniferatoxin | 1 | — |
| Krishnan et al. (74) | 0.01% in the diet | 1 | Capsazepine | 10 | Troglitazone |
| Zhang et al. (71) | 0.01% in the diet | 0.01, 0.1, and 1 | Capsazepine | 1 | — |
1The table describes the concentrations of Caps used in vivo and in vitro for each of the included studies, as well as which antagonists were used and their respective concentrations. The last column also describes the use of other agonists. Caps, capsaicin.